CardiaTec, a Cambridge, England, UK-based TechBio company employing computational methods to decode the biology behind cardiovascular disease, raised $6.5M in seed funding.
The round was led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures, as well as individual investors Dr. Maximilien Levesque, CEO & Co-Founder of Aqemia, and Naheed Kurji, former President of Recursion Pharmaceuticals Canada and CEO & Founder of Cyclica. In addition, the company added Dr. Joseph Lehár, former SVP of R&D Strategy at TechBio company Owkin, to its Scientific Advisory Board.
The company intends to use the funds to expand its platform and progress proprietary drug targets to wet lab validation.
CardiaTec leverages large multi-omics human data to navigate complex cardiovascular disease biology to identify novel and more targeted therapeutics. To support its approach, the company is building a proprietary human heart tissue multi-omics dataset. It also has a network of over 65 hospitals across the US and the UK, screening patients on a 24/7 basis to support the bespoke collection of human hearts for its data generation.
CardiaTec, a spin-out from the Han Lab at the University of Cambridge, was co-founded by Raphael Peralta (CEO and Laidlaw Scholar alumnus), Thelma Zablocki (COO), and Prof. Namshik Han (CTO).
FinSMEs
11/09/2024